Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals SG&A — Selling and marketing expenses by Quarter
SG&A — Selling and marketing expenses ($M) ($M)
Vertex Pharmaceuticals SG&A — Selling and marketing expenses: $388M in Q2 2026, up 46.7% from a year earlier. That is the highest of the 10 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Segment Reporting — Significant Segment Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SG&A — Selling and marketing expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 388 | +46.7% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 314 | +30.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 319 | +36.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 278 | +28.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 265 | +34.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 241 | +25.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 234 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 217 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 196 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 192 | – | Form 10-Q (filed 2025-05-06) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals SG&A — Selling and marketing expenses ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/seg-selling
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.